Freise KJ - Search Results

1

Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.

Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Jones AK, et al. Among authors: freise kj. AAPS J. 2016 Sep;18(5):1192-1202. doi: 10.1208/s12248-016-9927-9. Epub 2016 May 27. AAPS J. 2016. PMID: 27233802 Clinical Trial.

2

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.

Salem AH, Agarwal SK, Dunbar M, Nuthalapati S, Chien D, Freise KJ, Wong SL. Salem AH, et al. Among authors: freise kj. J Clin Pharmacol. 2016 Nov;56(11):1355-1361. doi: 10.1002/jcph.741. J Clin Pharmacol. 2016. PMID: 27029823 Clinical Trial.

3

Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.

Freise KJ, Dunbar M, Jones AK, Hoffman D, Enschede SL, Wong S, Salem AH. Freise KJ, et al. Cancer Chemother Pharmacol. 2016 Oct;78(4):847-53. doi: 10.1007/s00280-016-3144-1. Epub 2016 Sep 1. Cancer Chemother Pharmacol. 2016. PMID: 27586967

4

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, Awni WM, Salem AH. Freise KJ, et al. Clin Pharmacokinet. 2017 May;56(5):515-523. doi: 10.1007/s40262-016-0453-9. Clin Pharmacokinet. 2017. PMID: 27638334 Clinical Trial.

5

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.

Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL. Salem AH, et al. Among authors: freise kj. Clin Drug Investig. 2017 Mar;37(3):303-309. doi: 10.1007/s40261-016-0485-9. Clin Drug Investig. 2017. PMID: 27910036 Clinical Trial.

6

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.

Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH. Freise KJ, et al. Hematol Oncol. 2017 Dec;35(4):679-684. doi: 10.1002/hon.2373. Epub 2016 Dec 16. Hematol Oncol. 2017. PMID: 27982454

7

Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.

Freise KJ, Shebley M, Salem AH. Freise KJ, et al. J Clin Pharmacol. 2017 Jun;57(6):796-804. doi: 10.1002/jcph.858. Epub 2017 Jan 4. J Clin Pharmacol. 2017. PMID: 28052338 Clinical Trial.

8

Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.

Parikh A, Gopalakrishnan S, Freise KJ, Verdugo ME, Menon RM, Mensing S, Salem AH. Parikh A, et al. Among authors: freise kj. Leuk Lymphoma. 2018 Apr;59(4):871-879. doi: 10.1080/10428194.2017.1361024. Epub 2017 Aug 10. Leuk Lymphoma. 2018. PMID: 28797193 Clinical Trial.

9

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients.

Li M, Dave N, Salem AH, Freise KJ. Li M, et al. Among authors: freise kj. Medicine (Baltimore). 2017 Sep;96(35):e7988. doi: 10.1097/MD.0000000000007988. Medicine (Baltimore). 2017. PMID: 28858138 Free PMC article. Review.

10

Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.

Freise KJ, Hu B, Salem AH. Freise KJ, et al. Eur J Clin Pharmacol. 2018 Apr;74(4):413-421. doi: 10.1007/s00228-017-2403-3. Epub 2018 Jan 4. Eur J Clin Pharmacol. 2018. PMID: 29302721 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters